Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
17.08.2022 - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA (adalimumab-bwwd), a biosimilar referencing .
Press release content from Business Wire. The AP news staff was not involved in its creation.
Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
May 3, 2021 GMT
KENILWORTH, N.J. (BUSINESS WIRE) May 3, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will host Organon management at a meeting with the investment community. Management will detail plans for how Organon is expected to drive sustainable growth and shareholder value as a standalone company.
“The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies. Organon, as a standalone company, will be better positioned to realize its potential and to have a meaningful impact, particularly in women’s health”, said Rob Davis, president, Merck. “We believe this transaction will create value for the patients both companies serve and